Companies Dominating the Kidney Cancer Drugs Landscape:
- AbbVie
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Arlak Biotech
- Apikos Pharma
- Astellas Pharma
- AstraZeneca Plc
- Amgen Inc.
- Biogen Inc.
- Baxter International Inc.
- Byer AG
- GlaxoSmithKline Plc
- JW Therapeutics
- Johnson & Johnson
- Merck & Co., Inc.
- Novo Nordisk A/S
The kidney cancer drugs market is competitive owing to the strong presence of established companies and the emergence of start-ups. The key players are investing heavily in the production of advanced kidney cancer drugs market. This move is set to increase their market reach and earn high profits. Industry giants are also adopting marketing tactics such as collaboration with research institutions to develop innovative kidney cancer drugs and partnerships with other players to boost their regional expansion. New companies are focused on the development of cutting-edge kidney cancer diagnostic and therapeutic solutions to stand out in the crowd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of kidney cancer drugs is evaluated at USD 7.27 billion.
The kidney cancer drugs market size was over USD 6.93 billion in 2024 and is projected to reach USD 13.9 billion by 2037, witnessing around 5.5% CAGR during the forecast period i.e., between 2025-2037.
North America industry is set to hold largest revenue share of 35% by 2037, owing to presence of well-developed healthcare infrastructure.
The major players in the market include AbbVie, Baxter International Inc., Byer AG, GlaxoSmithKline Plc, Johnson & Johnson, and Merck & Co., Inc.
